OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer exercised or converted 2,295 CYTK derivative securities | OQRO

Home
Insider trades
Cytokinetics
Officer exercised or converted 2,295 CYTK derivative securities

Insider trades

Insider trade

Officer exercised or converted 2,295 CYTK derivative securities

Traded Nov 4, 2025 · Filed Nov 5, 2025

CYTCytokineticsCYTK

2,295
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 4, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 5, 2025

OfficerOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-25-000029

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Nov 5, 2025, 12:23 AM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Fady Ibraham Malik

Relationship

Officer

Officer title

EVP Research & Development

Security

Incentive Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Nov 4, 2025

Transaction code

Shares / units

2,295

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

6,600

Ownership form

Direct

Amendment

Around the same time

Andrew CallosEVP, Chief Commercial Officer

Filed 10mo ago

15KShares · @ $23.26

Traded Dec 5, 2025 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew CallosEVP, Chief Commercial Officer

Filed 10mo ago

11KShares · @ $39.13

Traded Dec 5, 2025 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Andrew CallosEVP, Chief Commercial Officer

Filed 10mo ago

16KShares · @ $37.63

Traded Dec 5, 2025 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record